Bevacizumab is among the first targeted therapies used in oncology. For many indications where chemotherapy options had been exhausted and few other treatment modalities were available, it changed the treatment approach and brought patients prolonged progression-free survival or even overall survival. It has become a standard of care for many advanced cancers. What do we know today about this monoclonal antibody, first introduced in routine practice in 2005?
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
